Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
In our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/19/4678 |
| _version_ | 1797576140303368192 |
|---|---|
| author | Patrik Pöschke Peter A. Fasching Werner Adler Matthias Rübner Matthias W. Beckmann Carolin C. Hack Felix Heindl Arndt Hartmann Ramona Erber Paul Gass |
| author_facet | Patrik Pöschke Peter A. Fasching Werner Adler Matthias Rübner Matthias W. Beckmann Carolin C. Hack Felix Heindl Arndt Hartmann Ramona Erber Paul Gass |
| author_sort | Patrik Pöschke |
| collection | DOAJ |
| description | In our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positive disease with neoadjuvant chemotherapy. Descriptive analyses were performed, and logistic regression models and survival analyses were calculated for disease-free survival (DFS) and overall survival (OS). Among the 1373 patients, 930 (67.73%) had HER2-low-positive and 443 (32.27%) had HER2-0 tumors. Patients with HER2-0 tumors had a significantly better pathological complete response, 29.25% vs. 20.09%, and pathological complete response/in situ, 31.97% vs. 24.08%, than patients with HER2-low-positive tumors (<i>p</i> < 0.001; <i>p</i> = 0.003), regardless of the hormone receptor (HR) status. No statistically significant differences were observed for the HR-positive (<i>p</i> = 0.315; <i>p</i> = 0.43) or HR-negative subgroups (<i>p</i> = 0.573; <i>p</i> = 0.931). DFS and OS were significantly longer for HR-positive, HER2-low-positive patients (log-rank <i>p</i> = 0.02; <i>p</i> = 0.012). OS was significantly longer for HR-negative, HER2-0 patients (log-rank <i>p</i> = 0.032). No significant DFS differences were found for the HR-negative cohort (log-rank <i>p</i> = 0.232). For the overall cohort, no significant differences were noted between HER2-low-positive and HER2-0 patients, either for DFS (log-rank <i>p</i> = 0.220) or OS (log-rank <i>p</i> = 0.403). These results show different survival outcomes for HER2-0 and HER2-low-positive tumors relative to HR status. These different cohorts can be identified using standardized immunohistochemistry, even retrospectively. |
| first_indexed | 2024-03-10T21:48:59Z |
| format | Article |
| id | doaj.art-ca058434fd2c4ef9b06f8c5eba1f94d8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T21:48:59Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ca058434fd2c4ef9b06f8c5eba1f94d82023-11-19T14:08:59ZengMDPI AGCancers2072-66942023-09-011519467810.3390/cancers15194678Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant ChemotherapyPatrik Pöschke0Peter A. Fasching1Werner Adler2Matthias Rübner3Matthias W. Beckmann4Carolin C. Hack5Felix Heindl6Arndt Hartmann7Ramona Erber8Paul Gass9Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyDepartment of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyInstitute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC-ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyInstitute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC-ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander–Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, GermanyIn our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positive disease with neoadjuvant chemotherapy. Descriptive analyses were performed, and logistic regression models and survival analyses were calculated for disease-free survival (DFS) and overall survival (OS). Among the 1373 patients, 930 (67.73%) had HER2-low-positive and 443 (32.27%) had HER2-0 tumors. Patients with HER2-0 tumors had a significantly better pathological complete response, 29.25% vs. 20.09%, and pathological complete response/in situ, 31.97% vs. 24.08%, than patients with HER2-low-positive tumors (<i>p</i> < 0.001; <i>p</i> = 0.003), regardless of the hormone receptor (HR) status. No statistically significant differences were observed for the HR-positive (<i>p</i> = 0.315; <i>p</i> = 0.43) or HR-negative subgroups (<i>p</i> = 0.573; <i>p</i> = 0.931). DFS and OS were significantly longer for HR-positive, HER2-low-positive patients (log-rank <i>p</i> = 0.02; <i>p</i> = 0.012). OS was significantly longer for HR-negative, HER2-0 patients (log-rank <i>p</i> = 0.032). No significant DFS differences were found for the HR-negative cohort (log-rank <i>p</i> = 0.232). For the overall cohort, no significant differences were noted between HER2-low-positive and HER2-0 patients, either for DFS (log-rank <i>p</i> = 0.220) or OS (log-rank <i>p</i> = 0.403). These results show different survival outcomes for HER2-0 and HER2-low-positive tumors relative to HR status. These different cohorts can be identified using standardized immunohistochemistry, even retrospectively.https://www.mdpi.com/2072-6694/15/19/4678breast cancerneoadjuvant therapyprognosisHER2-low-positiveHER2-0HER2 |
| spellingShingle | Patrik Pöschke Peter A. Fasching Werner Adler Matthias Rübner Matthias W. Beckmann Carolin C. Hack Felix Heindl Arndt Hartmann Ramona Erber Paul Gass Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy Cancers breast cancer neoadjuvant therapy prognosis HER2-low-positive HER2-0 HER2 |
| title | Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy |
| title_full | Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy |
| title_fullStr | Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy |
| title_full_unstemmed | Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy |
| title_short | Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy |
| title_sort | clinical characteristics and prognosis of her2 0 and her2 low positive breast cancer patients real world data from patients treated with neoadjuvant chemotherapy |
| topic | breast cancer neoadjuvant therapy prognosis HER2-low-positive HER2-0 HER2 |
| url | https://www.mdpi.com/2072-6694/15/19/4678 |
| work_keys_str_mv | AT patrikposchke clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT peterafasching clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT werneradler clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT matthiasrubner clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT matthiaswbeckmann clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT carolinchack clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT felixheindl clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT arndthartmann clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT ramonaerber clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy AT paulgass clinicalcharacteristicsandprognosisofher20andher2lowpositivebreastcancerpatientsrealworlddatafrompatientstreatedwithneoadjuvantchemotherapy |